The pharmacokinetics of [18F]UCB-H revisited in the healthy non-human primate brain.
Sébastien GoutalMartine GuillermierGuillaume BeckerMylène GaudinYann BramoulléAndré LuxenChristian LemaireAlain PlenevauxEric SalmonPhilippe HantrayeOlivier BarretNadja Van CampPublished in: EJNMMI research (2021)
Modeling issues with a 2TCM due to a slow component have previously been reported for other SV2A ligands with low specific binding, or after blocking of specific binding. As all SV2A ligands share chemical structural similarities, we hypothesize that this slow binding component is common for all SV2A ligands, but only hampers quantification when specific binding is low.